Kalytera Therapeutics Inc, formerly Santa Maria Petroleum Inc. is a Canada-based company, engaged in the development of cannabinoid (CBD) therapeutics. The Company is developing CBD formulations and prodrugs to target specific disease sites within the body. The Company's development programs include Bone Fracture Healing, Osteogenesis Imperfecta, Osteoporosis and Osteoporosis in Prader-Willi syndrome (PWS). The Company is focused on the development of KAL436/9, which is a synthetic derivative of CBD that has been structurally modified to develop solubility in water to improve potency. Its KAL671 is a synthetic fatty acid amide and an endocannabinoid-like molecule that may restore bone in persons suffering from osteoporosis. The Company's researchers are exploring the ability for KAL671 to prevent bone loss in mice with genetic mutations designed to mimic aspects of PWS.